<!DOCTYPE html>
<html>
    <head>
        <title>Description | iGem Winter Project</title>
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <script type="module" src="https://unpkg.com/ionicons@5.5.2/dist/ionicons/ionicons.esm.js"></script>
        <script nomodule src="https://unpkg.com/ionicons@5.5.2/dist/ionicons/ionicons.js"></script>
        <link rel="stylesheet" href="../static/css/basic.css">
        <link rel="stylesheet" href="../static/css/load.css">
        <link rel="stylesheet" href="../static/css/pages.css">
        <link rel="stylesheet" href="../static/css/components.css">
    </head>
    <body>
        <!-- scroll progress bar -->
        <div class="scroll-progress"></div>
        
        <!-- Loading cast -->
        <div class="loading-container">
            <div class="loading-spinner-image">
                <img src="../static/img/loading.png" alt="Loading...">
            </div>
            <div class="loading-text">Loading...</div>
        </div>

        <!-- Topbar -->
        <div class="top_bar">
            <div class="menu_btn">
                <ion-icon name="menu-outline"></ion-icon>
            </div>
            <div class="logo_wrap">
                <a href="../index.html"><img id="team_logo" src="../static/img/test.jpeg" alt=""></a>
            </div>
            <div class="menu_wrap">
                <div id="project" class="menu_item menu_item_cur">
                    <div class="title">Project<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./description.html">Description</a></li>
                        <li><a href="./design.html">Design</a></li>
                        <li><a href="./implementation.html">Implementation</a></li>
                        <li><a href="./contribution.html">Contribution</a></li>
                        <li><a href="./safety.html">Safety</a></li>
                    </ul>
                </div>
                <div id="wetlab" class="menu_item">
                    <div class="title">Wet Lab<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./results.html">Results</a></li>
                        <li><a href="./proof.html">Proof</a></li>
                        <li><a href="./part.html">Part</a></li>
                        <li><a href="./protocol.html">Protocol</a></li>
                        <li><a href="./engineering.html">Engineering</a></li>
                        <li><a href="./measurement.html">Measurement</a></li>
                        <li><a href="./notebook.html">Notebook</a></li>
                    </ul>
                </div>
                <div id="drylab" class="menu_item">
                    <div class="title">Dry Lab<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./model.html">Model</a></li>
                        <li><a href="./software.html">Software</a></li>
                        <li><a href="./hardware.html">Hardware</a></li>
                    </ul>
                </div>
                <div id="human" class="menu_item">
                    <div class="title">Human Practice<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./hp.html">Integrated Human Practice</a></li>
                        <li><a href="./education.html">Education & Public Engagement</a></li>
                        <li><a href="./entrepreneurship.html">Entrepreneurship</a></li>
                    </ul>
                </div>
                <div id="team" class="menu_item">
                    <div class="title">Team<ion-icon name="caret-back-outline"></ion-icon></div>
                    <ul class="choice">
                        <li><a href="./attributions.html">Attributions</a></li>
                        <li><a href="./member.html">Member</a></li>
                    </ul>
                </div>
            </div>
        </div>
        
        <!-- Banner -->
        <!-- <div class="banner">
            <img src="../static/img/logo-footer.png" alt="Description Banner">
        </div> -->
        <!-- Page Title Background -->
        <div class="page-title-bg">
            <div class="bg-image" style="background-image: url('../static/img/logo-footer.png')"></div>
            <div class="overlay"></div>
            <div class="title-content">
                <h1>Description</h1>
            </div>
        </div>

        <!-- Main content wrapper -->
        <div class="main">
            <!-- Sidebar wrapper -->
            <div class="menubg">
                <div class="sidebar">
                    <!-- sidebar collapse button -->
                    <div class="menu-collapse-btn">
                        <ion-icon name="chevron-back-outline"></ion-icon>
                    </div>
                    
                    <!-- Background -->
                    <div class="t1">
                        <a href="#background">Background</a>
                    </div>

                    <!-- Core Technology -->
                    <div class="t1">
                        <span>Core Technology</span>
                        <div class="t2">
                            <a href="#innovative-solution">Innovative Solution: Contact Lens-Based Drug Delivery System</a>
                            <a href="#molecular-mechanisms">Molecular Mechanisms of Cataracts and Therapeutic Challenges</a>
                            <a href="#drug-design">Drug Molecular Design and Optimization</a>
                            <a href="#advantages">Advantages of Contact Lenses in Drug Delivery</a>
                            <a href="#pharmacokinetics">Pharmacokinetics and Concentration Optimization</a>
                            <a href="#validation">Model Validation and Experimental Analysis</a>
                        </div>
                    </div>

                    <!-- Outlook -->
                    <div class="t1">
                        <a href="#outlook">Outlook and Potential Applications</a>
                    </div>

                    <!-- References -->
                    <div class="t1">
                        <a href="#references">Reference</a>
                    </div>
                </div>
            </div>

            <!-- sidebar expand button -->
            <div class="menu-expand-btn">
                <ion-icon name="chevron-forward-outline"></ion-icon>
            </div>

            <!-- Content area -->
            <div class="content">
                <section id="background">
                    <h1>Background</h1>
                    <p>"The eyes are the windows to the soul." Leonardo da Vinci's famous quote perfectly captures the significance of vision in human perception of the world. However, cataracts, the most common cause of blindness globally<sup><a href="#ref1">[1]</a></sup>, impact millions annually, particularly among middle-aged and elderly populations.</p>
                    
                    <figure>
                        <img src="../static/img/1.png" alt="Cataract prevalence">
                        <figcaption>Figure 1: Age-standardised prevalence of blindness, moderate vision impairment, and severe vision impairment because of cataract in 2020</figcaption>
                    </figure>
                    
                    <p>Currently, the mainstream treatment for cataracts involves surgically removing the clouded lens and replacing it with an artificial intraocular lens. While this method is considered the gold standard by the American Academy of Ophthalmology<sup><a href="#ref2">[2]</a></sup>, it demands significant medical resources and is not widely accessible in underdeveloped regions...</p>
                </section>

                <section id="core-technology">
                    <h1>Core Technology</h1>
                    
                    <section id="innovative-solution">
                        <h2>Innovative Solution: Contact Lens-Based Drug Delivery System</h2>
                        <p>Our project proposes a groundbreaking approach: using contact lenses as a drug delivery vehicle. By combining bioengineering and modern materials science, we designed a contact lens capable of sustained drug release. Utilizing a biohydrogel form that already secretes hyaluronic acid for dry eye treatment<sup><a href="#ref6">[6]</a></sup>, we modified the system to also release RNF114 for cataract therapy<sup><a href="#ref7">[7]</a></sup>. This dual-function contact lens addresses the limitations of traditional treatments by:</p>
                        
                        <ul>
                            <li>
                                <p>Enabling continuous drug release and targeted delivery to the lens.</p>
                            </li>
                            <li>
                                <p>Reducing the frequency of drug administration while aiming to increase average drug concentration and minimize systemic toxicity.</p>
                            </li>
                        </ul>
                    </section>

                    <section id="molecular-mechanisms">
                        <h2>Molecular Mechanisms of Cataracts and Therapeutic Challenges</h2>
                        <p><strong>Cataract formation</strong> is closely linked to protein misfolding and aggregation in the lens, with the small heat shock protein CRYAA playing a pivotal role. When CRYAA function is compromised due to environmental stress (e.g., low temperatures, oxidative conditions) or genetic mutations (e.g., the CRYAA Y118D mutation), its molecular chaperone activity is diminished, accelerating protein aggregation and insoluble deposits. These aggregates result in lens opacification, leading to visual impairment and, eventually, blindness<sup><a href="#ref8">[8]</a></sup><sup><a href="#ref9">[9]</a></sup><sup><a href="#ref10">[10]</a></sup><sup><a href="#ref11">[11]</a></sup>.</p>
                        
                        <p>To disrupt this vicious cycle, our team selected the <strong>E3 ubiquitin ligase RNF114</strong>, which can accurately identify misfolded CRYAA proteins and tag them for degradation via ubiquitination. Studies have demonstrated RNF114's significant effectiveness in reducing lens opacity in cold-induced and oxidative stress-related cataract models<sup><a href="#ref7">[7]</a></sup>. This therapeutic target offers an unprecedented opportunity for innovation.</p>

                        <p><strong>Key Technological Modules:</strong></p>
                        <ul>
                            <li>
                                <p><strong>Biohydrogel Platform:</strong> Leveraging biohydrogel as the foundational material for the contact lens, with engineered micro bioreactors positioned at the lens periphery (outside the visual field). These bioreactors continuously secrete therapeutic components such as RNF114 protein and hyaluronic acid, facilitating long-term drug delivery.</p>
                            </li>

                            <figure>
                                <img src="../static/img/2.jpg" alt="Design and composition">
                                <figcaption>Figure 2: Design and composition of the living self-lubricating CL. Created with BioRender.com.</figcaption>
                            </figure>

                            <figure>
                                <img src="../static/img/3.png" alt="Transparent hydrogel discs">
                                <figcaption>Figure 3: Transparent PVA-VS/PVA 100:0 hydrogel discs. Scale corresponds to 1 cm.</figcaption>
                            </figure>

                            <li>
                                <p><strong>Dual Treatment for Dry Eyes and Cataracts:</strong> The hyaluronic acid secretion not only lubricates the eye surface, alleviating dry eyes caused by prolonged lens wear, but also creates a stable environment for the sustained release of other therapeutic agents.</p>
                            </li>

                            <li>
                                <p><strong>Targeted Drug Delivery:</strong> Through molecular modifications, the drug gains enhanced permeability across the cornea and specific action on the lens, ensuring both efficacy and stability.</p>
                            </li>
                        </ul>
                    </section>

                    <section id="drug-design">
                        <h2>Drug Molecular Design and Optimization</h2>
                        <ul>
                            <li>
                                <p><strong>Enhanced Permeability:</strong> TAT peptide technology is employed to modify the RNF114 protein with short peptide sequences, boosting its transmembrane capability. This technology has been shown to enhance the ability of proteins to traverse barriers such as the blood-brain barrier and the corneal barrier, although the intact corneal epithelium can act as a barrier to penetration, which can be overcome by disrupting the epithelium<sup><a href="#ref12">[12]</a></sup>. Flexible linker peptides ensure that the three-dimensional structure of RNF114 remains intact, facilitating smooth passage through the corneal barrier.</p>
                            </li>
                            <li>
                                <p><strong>Stability Improvements:</strong> To address RNF114's susceptibility to degradation, PEGylation and glycosylation techniques are used to reduce immunogenicity and enhance stability within the ocular environment. Using the ExPASy tool, degradable sites on the protein were predicted, and positively charged lysine and arginine residues were selectively modified to mitigate degradation risks.</p>
                            </li>
                            <li>
                                <p><strong>Targeted Delivery Modifications:</strong> To ensure RNF114 precisely reaches the lens, we are considering lens-specific receptors (IGF1R or aquaporin AQP0). Their high specificity is critical for accurate drug delivery.</p>
                            </li>
                        </ul>

                        <h3>Chassis Design and Production Method</h3>
                        <p>To ensure stable drug expression and production, we employed engineered yeast as a biological chassis. Yeast offers several advantages:</p>
                        <ul>
                            <li>
                                <p>As a eukaryotic organism, it can perform post-translational modifications such as glycosylation and disulfide bond formation, which are essential for protein stability and function.</p>
                            </li>
                            <li>
                                <p>It secretes proteins efficiently, simplifying the drug purification process.</p>
                            </li>
                            <li>
                                <p>It provides a cost-effective and scalable platform for biopharmaceutical production.</p>
                            </li>
                        </ul>

                        <h3>Analysis of Key Ocular Barriers</h3>
                        <p>To optimize drug delivery efficiency, we analyzed several ocular barriers:</p>
                        <ul>
                            <li>
                                <p><strong>Tear Film Clearance Mechanism:</strong> Research indicates that 80%-90% of drugs administered via eye drops are eliminated through the nasolacrimal duct, with less than 5% reaching the intraocular tissues. By covering the cornea and integrating into the tear film, contact lenses reduce this loss significantly.</p>
                            </li>
                            <li>
                                <p><strong>Corneal Absorption Barrier:</strong> While the corneal epithelium is permeable to lipophilic drugs, hydrophilic drugs depend on paracellular transport through the stroma. Our design balances lipophilicity and hydrophilicity to improve permeability.</p>
                            </li>
                            <li>
                                <p><strong>Aqueous Humor Dynamics:</strong> By modeling drug distribution and metabolism in the anterior chamber, we ensure that RNF114 achieves effective therapeutic concentrations in the lens while avoiding rapid elimination.</p>
                            </li>
                        </ul>
                    </section>

                    <section id="advantages">
                        <h2>Advantages of Contact Lenses in Drug Delivery</h2>
                        <p>Compared to conventional eye drops, drug-loaded contact lenses provide significant technological advantages:</p>
                        <ul>
                            <li>
                                <p><strong>Prolonged Drug Retention:</strong> Contact lenses adhere closely to the eye surface, significantly reducing the loss of medication due to blinking or tear drainage. This design dramatically improves drug retention time within tear film, enhancing utilization efficiency.</p>
                            </li>
                            <li>
                                <p><strong>Sustained Drug Release:</strong> The hydrogel structure of the contact lenses facilitates controlled, long-term release of therapeutic agents, ensuring stable concentrations at the target site and reducing the need for frequent administration.</p>
                            </li>
                        </ul>
                    </section>
                </section>

                <section id="pharmacokinetics">
                    <h2>Pharmacokinetics and Concentration Optimization</h2>
                    <p>RNF114, being a small molecule protein, is prone to rapid diffusion and clearance, potentially leading to suboptimal concentrations in the lens. To address this, we incorporated a "sustained release system" within the contact lens. This system enables long-term expression of the therapeutic agent, maintaining a stable and high concentration in the ocular environment without inducing toxicity.</p>
                </section>

                    <section id="validation">
                        <h2>Model Validation and Experimental Analysis</h2>
                        <p>To verify the feasibility of our design, we conducted multi-tiered experiments:</p>
                        <ul class="validation-steps">
                            <li>
                                <p><strong>Molecular Modeling and Structural Prediction:</strong> Using AlphaFold, we predicted the spatial structure of TAT peptides conjugated to RNF114, ensuring that the modified protein retains its activity.</p>
                            </li>
                            <li>
                                <p><strong>[TODO: Place hold for Dry Lab Content]:</strong> Additional validation steps and experimental results to be added by the Dry Lab team.</p>
                            </li>
                        </ul>
                    </section>
                </section>

                <section id="outlook">
                    <h1>Outlook and Potential Applications</h1>
                    <p>Our contact lens drug delivery platform represents a revolutionary solution for cataract treatment and opens new possibilities for other ocular diseases. Its modular design allows for broad adaptability, targeting conditions such as glaucoma, retinal disorders, and beyond.</p>
                    
                    <p>By transforming contact lenses from a visual aid into a medical delivery vehicle, we bridge modern biotechnology and material science, offering groundbreaking advancements for ophthalmic medicine.</p>
                    
                    <blockquote class="quote">
                        <p>As William Osler once said, "Medicine is a science of uncertainty and an art of probability." With this innovation, we aim to bring clarity and hope to millions affected by vision loss.</p>
                    </blockquote>
                </section>

                <section id="references">
                    <h1>Reference</h1>
                    <div class="reference-list">
                        <div class="reference-item" id="ref1">
                            <span class="ref-number">[1]</span>
                            <span class="ref-content">Cicinelli, M. V., Buchan, J. C., Nicholson, M., Varadaraj, V., & Khanna, R. C. (2023). Cataracts. <em>Lancet</em>, 401(10374), 377-389.</span>
                            <a href="https://doi.org/10.1016/S0140-6736(22)01839-6" class="ref-link" target="_blank">DOI: 10.1016/S0140-6736(22)01839-6</a>
                        </div>

                        <div class="reference-item" id="ref2">
                            <span class="ref-number">[2]</span>
                            <span class="ref-content">Miller, K. M., et al. (2022). Cataract in the Adult Eye Preferred Practice Pattern. <em>Ophthalmology</em>, 129(1), P1-P126.</span>
                            <a href="https://doi.org/10.1016/j.ophtha.2021.10.006" class="ref-link" target="_blank">DOI: 10.1016/j.ophtha.2021.10.006</a>
                        </div>

                        <div class="reference-item" id="ref3">
                            <span class="ref-number">[3]</span>
                            <span class="ref-content">Thrimawithana, T. R., et al. (2018). Drug delivery to the lens for the management of cataracts. <em>Advanced Drug Delivery Reviews</em>, 126, 185-194.</span>
                            <a href="https://doi.org/10.1016/j.addr.2018.03.009" class="ref-link" target="_blank">DOI: 10.1016/j.addr.2018.03.009</a>
                        </div>

                        <div class="reference-item" id="ref4">
                            <span class="ref-number">[4]</span>
                            <span class="ref-content">Lee, B. J., & Afshari, N. A. (2023). Advances in drug therapy and delivery for cataract treatment. <em>Current Opinion in Ophthalmology</em>, 34(1), 3-8.</span>
                            <a href="https://doi.org/10.1097/ICU.0000000000000910" class="ref-link" target="_blank">DOI: 10.1097/ICU.0000000000000910</a>
                        </div>

                        <div class="reference-item" id="ref5">
                            <span class="ref-number">[5]</span>
                            <span class="ref-content">Chen, Y., Ye, Z., Chen, H., & Li, Z. (2024). Breaking Barriers: Nanomedicine-Based Drug Delivery for Cataract Treatment. <em>International Journal of Nanomedicine</em>, 19, 4021-4040.</span>
                            <a href="https://doi.org/10.2147/IJN.S463679" class="ref-link" target="_blank">DOI: 10.2147/IJN.S463679</a>
                        </div>

                        <div class="reference-item" id="ref6">
                            <span class="ref-number">[6]</span>
                            <span class="ref-content">Puertas‐Bartolomé, M., Gutiérrez‐Urrutia, I., Teruel‐Enrico, L. L., et al. (2024). Self‐Lubricating, living contact lenses. <em>Advanced Materials</em>, 36(27).</span>
                            <a href="https://doi.org/10.1002/adma.202313848" class="ref-link" target="_blank">DOI: 10.1002/adma.202313848</a>
                        </div>

                        <div class="reference-item" id="ref7">
                            <span class="ref-number">[7]</span>
                            <span class="ref-content">Yang, H., Ping, X., Zhou, J., et al. (2024). Reversible cold-induced lens opacity in a hibernator reveals a molecular target for treating cataracts. <em>Journal of Clinical Investigation</em>, 134(18), e169666.</span>
                            <a href="https://doi.org/10.1172/JCI169666" class="ref-link" target="_blank">DOI: 10.1172/JCI169666</a>
                        </div>

                        <div class="reference-item" id="ref8">
                            <span class="ref-number">[8]</span>
                            <span class="ref-content">Moreau, K. L., & King, J. A. (2012). Protein misfolding and aggregation in cataract disease and prospects for prevention. <em>Trends in Molecular Medicine</em>, 18(5), 273-82.</span>
                            <a href="https://doi.org/10.1016/j.molmed.2012.03.005" class="ref-link" target="_blank">DOI: 10.1016/j.molmed.2012.03.005</a>
                        </div>

                        <div class="reference-item" id="ref9">
                            <span class="ref-number">[9]</span>
                            <span class="ref-content">Sprague-Piercy, M. A., Rocha, M. A., Kwok, A. O., & Martin, R. W. (2021). α-Crystallins in the Vertebrate Eye Lens: Complex Oligomers and Molecular Chaperones. <em>Annual Review of Physical Chemistry</em>, 72, 143-163.</span>
                            <a href="https://doi.org/10.1146/annurev-physchem-090419-121428" class="ref-link" target="_blank">DOI: 10.1146/annurev-physchem-090419-121428</a>
                        </div>

                        <div class="reference-item" id="ref10">
                            <span class="ref-number">[10]</span>
                            <span class="ref-content">Shiels, A., & Hejtmancik, J. F. (2021). Inherited cataracts: Genetic mechanisms and pathways new and old. <em>Experimental Eye Research</em>, 209, 108662.</span>
                            <a href="https://doi.org/10.1016/j.exer.2021.108662" class="ref-link" target="_blank">DOI: 10.1016/j.exer.2021.108662</a>
                        </div>

                        <div class="reference-item" id="ref11">
                            <span class="ref-number">[11]</span>
                            <span class="ref-content">Budnar, P., Tangirala, R., Bakthisaran, R., & Rao, C. M. (2022). Protein Aggregation and Cataract: Role of Age-Related Modifications and Mutations in α-Crystallins. <em>Biochemistry (Moscow)</em>, 87(3), 225-241.</span>
                            <a href="https://doi.org/10.1134/S000629792203004X" class="ref-link" target="_blank">DOI: 10.1134/S000629792203004X</a>
                        </div>

                        <div class="reference-item" id="ref12">
                            <span class="ref-number">[12]</span>
                            <span class="ref-content">Guo, X., Hutcheon, A. E., & Zieske, J. D. (2004). Transduction of functionally active TAT fusion proteins into cornea. <em>Exp Eye Res</em>, 78(5), 997-1005.</span>
                            <a href="https://doi.org/10.1016/j.exer.2003.12.010" class="ref-link" target="_blank">DOI: 10.1016/j.exer.2003.12.010</a>
                        </div>
                    </div>
                </section>
            </div>
        </div>

        <!-- Footer -->
        <footer id="footer">
            <div class="logo_wrap">
                <img id="team_logo" src="../static/img/logo-footer.png" alt="">
            </div>
            <div class="follow">
                <div class="title">Follow Us</div>
                <ul class="follow_list">
                    <li><a href="https://space.bilibili.com/700401359?spm_id_from=333.337.search-card.all.click" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-bilibili.png" alt=""></a></li>
                    <li><a href="https://twitter.com/ZjuChina" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-twitter.png" alt=""></a></li>
                    <li><a href="https://mp.weixin.qq.com/s/yTMIiH4AQ2skqP-7cXr7Ig" target="_blank"><img src="https://static.igem.wiki/teams/4202/wiki/t-zju-china-wechat.png" alt=""></a></li>
                </ul>
            </div>
            <div class="contact">
                <div class="title">Contact Us</div>
                <div class="email">ZJU_China@outlook.com</div>
            </div>
        </footer>
        <script src="../static/js/basic.js"></script>
        <script src="../static/js/pages.js"></script>
    </body>
</html>